🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tandem’s much awaited Mobi automated insulin delivery system is now available in the US, making it the world’s smallest insulin delivery system to be fully controllable by a smartphone for ages 2 and older. Find out everything you need to know - bit.ly/3D6Talg

Dexcom G7 direct to watch is FDA cleared. It’s worth a FINALLY. Rollout to all G7 users by the end of June. #ATTD2024

We have a brand new CGM…. from Roche. Accu-Chek SmartGuide. Summary: ➡️ 14 day sensor ➡️ 1-calibration on day 1 needed ➡️ Low and overnight hypo predictions ➡️ Internet required for predictions to work ➡️ Not CE marked yet ➡️ Upper arm #ATTD2024

Omnipod5 approved in 🇨🇦 today!!!

Original Article: Insulin Efsitora or Degludec in Type 2 Diabetes without Previous Insulin (QWINT-2) nej.md/3Xuarje Editorial: A New Once-Weekly Insulin — Its Effectiveness and Safety nej.md/47lPk68 #EASD2024 | EASD

Treatment with Semaglutide improves osteoarthritis pain in patients with obesity 🦴 New data from NEJM trial. We are expected to see similar results from Tirzepatide trial. nejm.org/doi/full/10.10…

Today is #WorldDiabetesDay! Let’s stop #diabetes stigma! The right words go a long way. 💙 Be inclusive. 💙 Be kind. 💙 Be respectful. bit.ly/40QWn5o

Over 800 million adults are now living with diabetes worldwide with more than half not receiving treatment, global analysis suggests. On #WorldDiabetesDay, explore the data: hubs.li/Q02Yb3Fg0

Working hard to raise awareness for #WorldDiabetesDay Halton Healthcare Diabetes Canada #teamblue #diabetes

(1/x) Here's a potentially fatal flaw in how thyroid storm is taught in medical school & residency —and why sticking to the textbook can be deadly for your sickest thyroid storm patients. ⚡️⚡️⚡️ I've seen this happen several times. A 🧵 #FOAMed #MedTwitter #endocrine #FOAMcc

7.2mg once weekly semaglutide in 1,407 PPL with obesity over 72 weeks #weightloss

Two years of empagliflozin slowed kidney disease progression and reduced cardiovascular risk. In the follow-up study to the EMPA-KIDNEY trial, empagliflozin had additional cardiorenal benefits after discontinuation. Full study results and Research Summary: nej.md/3NE3W7K

More evidence from Ontario supporting the use of CGM for improving glucose control and reducing ER visits and hospitalization in people with #T2D using #insulin or non-insulin therapies dom-pubs.onlinelibrary.wiley.com/doi/full/10.11…

Should we be prescribing GLP1 receptor agonists in pre-diabetes + overweight? You certainly will substantially reduce the lifetime risk of diabetes as data from SURMOUNT trial demonstrates. But, the $ Cost of treatment and duration remains in question. nejm.org/doi/full/10.10…

Evidence continues to grow on efficacy of GLP1 receptor agonists in alcohol use disorder. This trial shows reductions in alcohol cravings, but not average drinks per calendar day jamanetwork.com/journals/jamap…

Very excited about Omnipod 5 arrival in Canada. Compatibility will be with Dexcom G6/7. Partial closed loop systems have been so instrumental in the care of patients with T1DM, and I can't wait for more patients to experience it! 🙂 #omnipod

In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM

Findings from a new study suggest a significant paradigm shift in the field of hypertension. Researchers from UCalgaryMedicine say confirmatory testing for primary aldosteronism, a common cause of #hypertension, often misinforms care and should be removed from the diagnostic care

Presented at #ADASciSessions: In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body-weight reduction in adults without diabetes and with overweight or obesity. Full trial results: nej.md/444aW7f

Presented at #ADASciSessions: The MariTide phase 2 trial of once-monthly maridebart cafraglutide, a peptide–antibody conjugate, showed substantial weight reduction in participants with obesity with or without type 2 diabetes. Full trial results: nej.md/3ZHxLeb